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Amyotrophic lateral sclerosis (ALS) includes a number of disorders causing degene-
ration of lower and upper motor neurons and findings in the bulbar region and at least two 
spinal regions or UMN and LMN in three spinal regions. ALS is typically presented with bulbar or 
asymmetric limb weakness, loss of ability to speak, to swallow and to breathe. Kennedy disease 
is a form of MND that is associated with bulbar involvement and X linked recessive inheritance. 
The symptoms include muscular cramps, a limb-girdle distribution of muscle weakness, bulbar 
symptoms and distinguishing clinical features include facial and perioral fasciculations in par-
ticular. This is a case study of a 43-year- old man who suffered from recurrent muscle cramp-
ing and progressive symmetric lower extremity weakness, with a prominent fatigable compo-
nent to this weakness, shoulder weakness, difficulty swallowing and facial twitching. EMNG 
showed widespread reinnervation changes and fasciculations in arms, legs, tongue, and thora-
cic paraspinals, with minimal fibrillation potentials. Motor NCS were normal or borderline in am-
plitude, and sensory responses were absent in upper and lower limbs. Genetic testing was 
positive (45 CAG). Kennedy disease may be underdiagnosed, owing in part to misdiagnosis and 
to the mild symptoms exhibited by some patients. The electro-physiological examinations are 
the key point to the diagnosis of Kennedy disease. In our case, we found the symmetric weak-
ness, sensory abnormalities on electrophysiological testing, prominent facial fasciculations, and 
gynecomastia which were not characteristic of the ALS, and indicated that was one of MND 
syndromes such as Kennedy disease and that was confirmed by genetic testing. 
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Introduction 
 
The differential diagnosis of amyotrophic late-
ral sclerosis (ALS) includes a number of disorders 
causing degeneration of lower and upper motor ne-
urons. It is important to consider these diagnoses 
because the prognosis is often better and in certain 
situations, specific treatments may be available. (1)  
ALS is defined on clinical evidence and requi-
res both upper motor neuron - UMN ( such as spas-
tic tone, hiperreflexia, and Babiski sign) and lower 
motor neuron - LMN (including muscle atrophy, fas-
ciculations and weakness) and findings in the bulbar 
region and at least two spinal regions (cervical, tho-
racic, lumbosacral) or UMN and LMN in three spinal 
regions. A patient with ALS typically presents with 
bulbar or asymmetric limb weakness, more promi-
nent in distal than in proximal muscles. Most pati-
ents with ALS will lose their ability to control their 
limbs, to speak, to swallow and to breathe (1). With-
out mechanical ventilation, death from respiratory 
failure typically ensues within 3 to 5 years of the 
onset of symptoms. The typical age of ALS onset is 
60 years. Some patients have comorbid frontotem-
poral dementia and strong family history - familial 
ALS accounts for 3 to 10 % of all ALS forms while at 
least 90% have none -sporadic ALS. In recent years, 
14 different genes have been identified that cause 
various types of motor neuron disease. The best evi-
dence for this involves the protein TDP-43 in the 
intraneuronal cytoplasmatic protein aggregates of 
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SALS and in some forms of FALS. Another example, 
within FALS 1 has a mutation in SOD1 (2). 
ALS continues to be diagnosed and followed 
almost entirely on the basis of clinical findings. There 
is no laboratory test to prove or disapprove the dia-
gnosis. For patients with classic presentation routine 
chemistries, complete blood count, serum kinases , 
electrophysiologic testing, and imaging studies of the 
spine/brain are performed. More extensive labora-
tory testing should be reserved or more atypical pre-
sentations (pure UMN or LMN syndromes, the dise-
ase of early onset under 40 years of age or prolong-
ed duration, coexistent systemic illness or the pre-
sence of sensory or urinary symptoms). Diagnostic 
CSF biomarkers may allow for improved diagnosis of 
ALS, may be leading to the ability to make diagnosis 
definitively in early cases. Routine testing for heavy 
metals in the serum or urine is not indicated unless 
there is a high suspicion for exposure. Another labo-
ratory study that may support the diagnosis of ALS 
is muscle biopsy. 
Multiple studies have shown that a multidis-
ciplinary approach may prolong survival and impro-
ve the quality of life of patients with ALS (3). Only 
one drug has ever been shown to prolong survival in 
patients with ALS: riluzole. Riluzole affects neurons 
by three mechanisms: inhibiting excitatory amino 
acid release, inhibiting events after stimulation of 
excitatory amino acid receptors and stabilizing the 
inactivated state of voltage-dependent sodium chan-
nels (3). Palliative care and symptomatic therapy 
play an integral part in the management of patients 
with ALS. That included exercises, hydrotherapy, and 
the drugs baclofen, gabapentin, amitriptyline when 
there is comorbid sleep disturbance, depression or 
pseudobulbar affect (4). 
The motor neuron disease (MND) that may 
present clinically with progressive dysfunction of mo-
tor neurons are included in the differential diagnosis 
ALS. MND includes the spectrum of clinical syndro-
mes that result from degeneration of upper motor 
neurons, lower motor neurons or both. One of the 
syndromes is Kennedy disease. 
Kennedy disease is a form of MND that is as-
sociated with bulbar involvement and X linked reces-
sive inheritance (5). 
The disease affects only males, usually at the 
beginning of the third or fourth decade of life. The 
initial symptoms include muscular cramps, a limb-
girdle distribution of muscle weakness, and bulbar 
symptoms. Distinguishing clinical features include 
facial and perioral fasciculations, in particular, which 
are present in more than 85 % of patients, hand 
tremor, and tongue atrophy associated with a longi-
tudinal midline furrow. There is no evidence of UMN 
involvement and sensory examination is typically 
normal. Other systemic manifestations include gyne-
comastia in 60-90 % of patients due to elevated go-
nadotropin levels associated with testicular atrophy, 
feminization, impotence, and infertility (6). Diabetes 
mellitus is seen in 10-20 % of patients. Genetic test-
ing can be performed to confirm the presence of an 
abnormal trinucleotide repeat expansion (CAG) in 
the androgen receptor gene on the X chromosome. 
In healthy individuals, the repeats range from 17 to 
26 in this coding area, whereas in Kennedy disease, 
the number of repeats ranges from 40 to 65. The 
number of the enlarged CAG repeats is significantly 
correlated with the age of onset but has no correla-
tion with severity of weakness, degree of sensory 
neuropathy, of gynecomastia or impotence (7). 
 
Materials and methods 
 
This is a case study of a 43 - year-old man 
who was referred for a second opinion regarding the 
diagnosis of ALS. He reported recurrent muscle cram-
ping since he was 25 and progressive symmetric 
lower extremity weakness 4 years ago. He noted a 
prominent fatigable component to this weakness, 
with worsening associated with prolonged use of the 
muscles. He had noted shoulder weakness, difficulty 
swallowing, and facial twitching. He denied a family 
history of neurologic illness. 
The examination has shown bifacial weakness 
with continuous facial fasciculations, proximal extre-
mity weakness, areflexia, and normal sensation. 
There was also weakness and atrophy of the tongue, 
mild nasal dysarthria, and significant axial weakness 
with lumbar lordosis. Postural tremor was noted in 
the upper extremities and frequent fasciculations 
were observed in the arms and legs. He had gyneco-
mastia. 
Serum CK level was elevated at 1800 IU/L. 
EMNG showed widespread reinnervation changes 
and fasciculations in arms, legs, tongue, and tho-
racic paraspinals, with minimal fibrillation potentials. 
Motor NCS were normal or borderline in amplitude, 
and sensory responses were absent in upper and 
lower limbs. SEP (n. medianus) showed that cortical 
responses and spinograms are morphologically se-
vere altered indicating a defect in the conduction in 
the central and peripheral roads SS bilaterally. SEP 
(n. tibialis) showed morphologically altered cortical 
responses with prolonged latencies. Spinograms were 
low volted with prolonged latencies. The finding sug-
gests a defect in the conduction in the central and 
peripheral roads SS bilaterally. 
Muscle biopsy showed inequality in the size of 
muscle fibers due to the presence of atrophic fibers 
with elongated, angular and rounded contours that 
meet in small groups. Increased core presents with 
centralization and rare fibers under phagocytosis. 
Interstitially, connective tissue was neat and vessels 
were with a neat wall and lumen. Genetic testing 
was positive for an expanded allele in CAG repeat 
region of the androgen receptor gene (45 CAG). MRI 
of the brain and spine were normal. 
 
Conclusion and discussion 
 
Kennedy's disease, also known as spinal and 
bulbar muscular atrophy (SBMA), is a rare, adult-on-
set, X-linked recessive neuromuscular disease with 
an estimated incidence of approximately 1 case in 
40,000 men, but the general impression is that 
Kennedy disease may be underdiagnosed, owing in 
part to misdiagnosis and to the mild symptoms exhi-
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bited by some patients. SBMA is caused by expan-
sion of a CAG repeat sequence in exon 1 of the an-
drogen receptor gene (AR) encoding a polygluta-
mine (polyQ) tract. The polyQ-expanded AR accu-
mulates in nuclei, and initiates degeneration and 
loss of motor neurons and dorsal root ganglia. While 
the disease has long been considered a pure lower 
motor neuron disease, recently, the presence of ma-
jor hyper-creatine-kinase (CK)-emia and myopathic 
alterations on muscle biopsy has suggested the pre-
sence of a primary myopathy underlying a wide ran-
ge of clinical manifestations (8). 
The electrophysiological examinations are the 
key point to the diagnosis of Kennedy disease. Ele-
ctroneurography shows normal conduction velocity 
in peripheral nerves, but the sensory nerves usually 
show axonal degeneration, which causes only very 
mild or subclinical neurological deficits. Electromyo-
graphy shows chronic anterior horn cell degenera-
tion in skeletal muscles. The molecular genetic dia-
gnosis was introduced in 1991 when on the abnor-
mal expansion of CAG repeat was found in the first 
exon of the androgen receptor gene on chromosome 
X with a frequency of 100 % in the affected popula-
tion. Since the progression is very slow and these 
patients can expect a normal life span, it is essential 
to this syndrome from other, often more severe di-
seases, such as ALS.  
In our case, we found symmetric weakness, 
sensory abnormalities on electrophysiological test-
ing, prominent facial fasciculations, and gynecomas-
tia which were not characteristic of the ALS, and 
indicated that is one of MND syndromes such as 
Kennedy disease and that was confirmed by genetic 
testing. Various endocrine abnormalities including 
decreased fertility and gynecomastia are common 
and among the first features of KD, what was the 
finding in our case also.  
Animal models of KD have demonstrated im-
provement on withdrawal of testosterone, indicating 
that this agonist of the androgen receptor is required 
for the toxic effect. Potential therapies based on te-
stosterone withdrawal in humans have shown some 
promise, but efficacy remains to be proven (9).   
Androgen deprivation, to gene silencing, an 
expanding repertoire of peripheral targets, including 
muscle and advancement of these strategies into 
the clinic, can be reasonably anticipated that the 
landscape of treatment options for SBMA and other 
neuromuscular conditions will change rapidly in the 
near future (10). 
To date, the abnormal expansion of CAG re-
peat has been identified to cause nine neurodegene-
rative diseases including SBMA, Huntington’s disease 
(HD), dentatorubral-pallidoluysian atrophy (DRPLA) 
and six forms of spinocerebellar ataxia (11). Altho-
ugh the causative gene varies with each disease, 
these polyglutamine disorders share common path-
ways of molecular pathogenesis, such as accumu-
lation of abnormal proteins, transcriptional dysregu-
lation and disruption of axonal transport (12). Ad-
ditionally, several lines of evidence suggest that 
mitochondrial impairment and elevated oxidative st-
ress are also implicated in the pathogenesis of Ken-
nedy’s disease (13). 
Despite several therapeutic attempts made in 
mouse models, no effective disease-modifying the-
rapy has been available yet, although symptomatic 
therapy is beneficial for the management of the 
weakness, fatigue and bulbar symptoms (8). The 
disease typically lasts at least 2-3 decades and life 
expectancy does not appear to be compromised 
(14). 
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Amiotrofična lateralna skleroza (ALS) uključuje višestruke poremećaje koji uzrokuju 
degeneraciju gornjeg i donjeg motoričnog neurona kao i promene u bulbarnom regionu i u 
najmanje dva spinalna područja ili GMN i DMN u tri spinalna područja. ALS se obično mani-
festuje bulbarnom ili asimetričnom slabošću ekstremiteta, gubitkom govorne sposobnosti, 
gutanja i disanja. Kenedijeva bolest je oblik MNB koji je povezan sa bulbarnim oštećenjem i X 
recesivnim naslednim oboljenjem. Simptomi uključuju mišićne spazme, mišićnu slabost eks-
tremiteta, bulbarne simptome, a klinički simptomi uključuju facijalnu i posebno perioralnu fas-
cikulaciju. Ovo je studija slučaja 43-godišnjeg čoveka sa rekurentnim mišićnim spazmama i 
progresivnom simetrijskom slabošću donjih ekstremiteta, praćen umorom, slabošću ramenog 
pojasa, teškoćama gutanja i grčevima lica. EMNG je pokazao promene u inervaciji i fasci-
kulaciji ruku, nogu, jezika i torakalno paraspinalno sa minimalnim potencijalima na fibrilaciju. 
Motorna brzina sprovodljivosti bila je normalna do granice amplitude, sa odsustvom senzor-
nog odgovora gornjih i donjih ekstremiteta. Genetičko testiranje bilo je pozitivno (45 CAG). 
Kenedijeva bolest može da bude subdijagnostifikovana, kao rezultat propuštene dijagnoze ili 
kao rezultat blagih simptoma kod bolesnika. Najvažniji deo dijagnoze su elektrofiziološki pre-
gledi. U našem slučaju pokazale su se simetrična slabost, senzorne abnormalnosti u elektro-
fiziološkom testiranju, facijalne fascikulacije i ginekomastija, koje nisu karakteristične za ALS, 
što zauzvrat ukazuje na to da se radi o nekom od MNB sindroma kao što je Kenedijeva bolest, 
što je potvrđeno genetskim testiranjem. 
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